Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q2 EPS of ($0.71), $0.08 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $12.09 million versus the consensus estimate of $22.11 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.